Novavax Announces Initial Omicron Cross-Reactivity Data from

- Two-dose primary regimen of NVX-CoV2373 demonstrated Cross-reactive immune responses against Omicron (B.1.1.529) and other variants
- Third dose produced ...

Related Keywords

, Development Of Vaccine , Nasdaq , Novavax Inc , Adolescent Studies , Omicron Specific Vaccine , Novavax , Nnounces , Nitial , Micron , Cross , Reactivity , Data , Rom , Covid , Vaccine , Rooster , End , Adolescent , Studies ,